BioSpace News Archive

Itamar Medical Ltd., a leading medical device and digital health company focused on the diagnosis of sleep apnea and other respiratory sleep disorders, reported preliminary unaudited revenue results for the third quarter 2020 and announced revenue guidance for the full year 2020.

Nathwani joins Dewpoint after serving as Chief Medical Officer, Chief Digital Officer, and Executive Committee member at Sanofi

Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation announced that MVC has obtained a Taiwan government subsidy for successfully initiating a Phase 1 clinical trial in Taiwan.

InspireMD, Inc., the developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by carotid artery disease, announced the addition of Gary Roubin, M.D., Ph.D., to InspireMD’s Board of Directors.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced positive findings from a study evaluating MN-001 in an acute liver injury model will be presented at The Liver Meeting Digital Experience™ 2020, an event of the American Association for the Study of Liver Diseases.

ProMIS’ proprietary drug discovery and development platform highlighted forability to create novel antibodies, diagnostics and vaccine candidates for neurodegenerative diseases

The most comprehensive data solution in the industry, comprised of over 215,000 cases of real-world patient records with integrated molecular and clinical outcomes data, offers an unmatched resource for developing a better understanding of the unique molecular mechanisms of cancer

Sales of $21.1 billion reflecting an overall and operational increase of 1.7%*, and adjusted operational increase of 2.0%* despite the estimated negative impact of the COVID-19 pandemic

Pediatric Patients Successfully Treated Utilizing 3mm Instruments on Digital Laparoscopy Platform

Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, announced that it has dosed the first patients in its Phase 2 clinical trial evaluating EDP1815 for the treatment of mild to moderate psoriasis.